Evaluation of Leishmania donovani Protein Disulfide Isomerase as a Potential Immunogenic Protein/Vaccine Candidate against Visceral Leishmaniasis by Kushawaha, Pramod Kumar et al.
Evaluation of Leishmania donovani Protein Disulfide
Isomerase as a Potential Immunogenic Protein/Vaccine
Candidate against Visceral Leishmaniasis
Pramod Kumar Kushawaha
1, Reema Gupta
1, Chandra Dev Pati Tripathi
1, Shyam Sundar
2,
Anuradha Dube
1*
1Division of Parasitology, Central Drug Research Institute, Lucknow, India, 2Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi,
India
Abstract
In Leishmania species, Protein disulfide isomerase (PDI) - a redox chaperone, is reported to be involved in its virulence and
survival. This protein has also been identified, through proteomics, as a Th1 stimulatory protein in the soluble lysate of a
clinical isolate of Leishmania donovani (LdPDI). In the present study, the molecular characterization of LdPDI was carried out
and the immunogenicity of recombinant LdPDI (rLdPDI) was assessed by lymphocyte proliferation assay (LTT), nitric oxide
(NO) production, estimation of Th1 cytokines (IFN-c and IL-12) as well as IL-10 in PBMCs of cured/endemic/infected
Leishmania patients and cured L. donovani infected hamsters. A significantly higher proliferative response against rLdPDI as
well as elevated levels of IFN-c and IL-12 were observed. The level of IL-10 was found to be highly down regulated in
response to rLdPDI. A significant increase in the level of NO production in stimulated hamster macrophages as well as IgG2
antibody and a low level of IgG1 in cured patient’s serum was observed. Higher level of IgG2 antibody indicated its Th1
stimulatory potential. The efficacy of pcDNA-LdPDI construct was further evaluated for its prophylactic potential.
Vaccination with this construct conferred remarkably good prophylactic efficacy (,90%) and generated a robust cellular
immune response with significant increases in the levels of iNOS transcript as well as TNF-a, IFN-c and IL-12 cytokines. This
was further supported by the high level of IgG2 antibody in vaccinated animals. The in vitro as well as in vivo results thus
indicate that LdPDI may be exploited as a potential vaccine candidate against visceral Leishmaniasis (VL).
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Introduction
Visceral Leishmaniasis (VL) is the most severe systemic disease
among the three main categories of leishmaniasis and affects
500,000 people every year [1,2]. Moreover, VL has emerged as an
opportunistic infection in HIV-1 infected patients in many parts of
the world [3,4,5]. Currently, there is no effective vaccine against
leishmaniasis and control of the disease is almost confined to
chemotherapy. There are only a limited number of drugs available
and each has its own disadvantages, as they require long-term
administration periods and often induce serious side-effects due to
their toxicity [6,7]. In addition, increasing incidence of drug-
resistant strains has hampered the control of the disease even by
chemotherapy [8,9,10,11]. Therefore, attention has now been
shifted towards the development of effective vaccines. Although
induction of lifelong protection against re-infection in individuals
who recovered from the disease, demonstrates that a protective
vaccine can be achieved, an effective vaccine against human
leishmaniasis has yet to be discovered [12].
The outcome of the typical symptomatic clinical form of VL is
critically influenced by the immune response developed by the
host wherein the systemic infection, with spread of the parasites to
the spleen, liver, lymph nodes, bone marrow and other organs, is
accompanied by a high titre of circulating antibodies and a
depression of Type 1 T-cell mediated immunity, with decreasing
production of IFN-c and IL-12 and a marked up-regulation of IL-
4 and IL-10 [13,14,15,16,17,18]. However, asymptomatic clinical
form in VL endemic regions is often followed by protective
immunity, where a predominant Type 1 T-cell response is
observed [19]. These findings suggest that any intervention that
helps the shift of the immune response from Th2 type toward Th1
type will have a major role in cure and prevention of VL.
Therefore, strategies to immune-potentiate the Th1 arm of the
immune response could be exploited for the development of
potential vaccine candidates. Further, genetic immunization is a
relatively new tool for achieving specific immune activation with
several advantages such as expression of concerned genes nearest
to its native form, induction of cellular immune response,
persistent expression of desired antigen and induction of memory
responses against the infectious disease [20]. Moreover, host cells
take up coding plasmids, transcribe and translate the encoded
gene, and produce proteins that stimulate an immune response
when presented to the immune system in the context of self-MHC
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shown to induce protective immunity through both MHC class I
and class II restricted T cell responses in a variety of infections
[24,25,26]. Therefore, the plasmid DNA encoding specific antigen
induced both CD4+ and CD8+ T cells, which is essential for
protection against intracellular diseases that require cell mediated
immunity like leishmaniasis [27]. However, DNA vaccines have
made little progress in the field of VL. Vaccination with the ORFF
gene induced both humoral and cellular immune responses against
ORFF, which provided a significant level of protection against
challenge with L. donovani in a mouse model [28]. Similarly, a
DNA vaccine based on kinetoplastid membrane protein 11
(KMP11) provided protection to golden hamsters against both
antimony-responsive and -resistant Leishmania strains developed
[29]. In an attempt to identify new antigens to be used as vaccines,
we focused on those proteins of Leishmania parasites which are Th1
stimulatory and supposed to be the effector molecules for defence
mechanism against Leishmania infection. Protein disulfide isomer-
ase (PDI) was identified through proteomics as one of the soluble
leishmanial protein that induced a Th1 response in the PBMCs of
Leishmania infected cured/endemic patients [30].
PDIs are essential enzymes that catalyze thiol-disulfide inter-
change, ensuring the proper folding and conformation of proteins,
acting as co-receptors of cell reorganization, and preventing cell
toxicity associated with ER stress and protein misfolding [31,32].
PDIs may also be involved in the host mucosal immune system,
inducing secretory IgA [33,34]. Although much has been learned
about PDIs in higher eukaryotes, limited information is available
regarding PDIs in pathogens that are important for human
infections. The protein has been reported to have role in Leishmania
virulence and survival [35]. The characterization of these
virulence factors obviously has important implications for the
design of new drugs or vaccines against Leishmania parasites. The
present study deals with the cloning, expression and purification as
well as molecular characterization of LdPDI. The protein was
further examined for the first time for its ability to 1) stimulate the
immune responses in leishmania infected cured/endemic contact
individuals’ PBMCs, 2) modulate the immune response in cured
hamsters infected with L. donovani and 3) protect the hamsters
against L. donovani challenge when administered as DNA vaccine.
The hamster (Mesocricetus auratus) has been proven to be the most
appropriate experimental model as it largely reflects the clinic-
pathological features of progressive human VL, including a
relentless increase in visceral parasitic burden, cachexia, hepato-
splenomegaly, pancytopenia, hypergammaglobulinemia and ulti-
mately death. Of late, it has also been used extensively for
vaccination studies [36,37].
Materials and Methods
Animal
Laboratory-bred male golden hamsters (Mesocricetus auratus, 45–
50 g) from the Institute’s animal house facility were used as
experimental host. They were housed in climatically controlled
room and fed with standard rodent food pellet (Lipton India Ltd.,
Bombay) and water ad libitum. The usage of hamsters was
approved by the Institute’s Animal Ethical Committee (protocol
number 150/09/Para/IAEC dated 23.10.2009).
Parasites
The L. donovani clinical strain was procured from a patient
admitted to the Kala-azar Medical Research Centre of the
Institute of Medical Sciences, BHU, Varanasi and was cultured in
vitro as described elsewhere [37]. Promastigotes were grown in
RPMI – 1640 medium at 26uC (Sigma, USA) in 75 cm
2 culture
flasks (Nunc) [38]. The strain has also been maintained in
hamsters through serial passage, i.e. from amastigote to amastigote
[38].
Preparation of soluble L. donovani promastigote antigen
Soluble L. donovani (SLD) promastigote antigen was prepared as
per method described by Gupta et al. [30]. Briefly, log phase
promastigotes (10
9) were harvested from 3 to 4 days of culture and
washed four times in cold phosphate-buffered saline (PBS) and
resuspended in PBS containing protease inhibitors cocktail (Sigma,
USA) and subjected to ultrasonication and centrifugation at
40,0006g for 30 min.The protein content of the supernatant was
estimated [39] and stored at 270uC.
Cloning, expression and purification of recombinant
LdPDI (rLdPDI)
L. donovani genomic DNA was isolated from 10
8 promastigotes,
washed and suspended in NET buffer (10 mM Tris-HCl (pH 7.5),
100 mM NaCl, and 1 mM EDTA) and incubated with proteinase
K (1 mg/ml; Invitrogen Life Technologies) and 0.5% SDS at
50uC for 4 h. Nucleic acids were extracted by phenol:chlorofor-
m:isoamyl alcohol extraction and ethanol precipitation. Genomic
DNA was spooled and subjected to RNase (100 mg/ml) treatment.
LdPDI gene was amplified using Taq Polymerase (Takara) lacking
a3 9–59 exonuclease activity. PCR was performed using LdPDI -
specific primers (based on the L. infantum - PDI gene sequence):
forward, 5-AAGCTTATGCAGCGCTCATTCCTTGC-3 and
reverse, 5- GCGGCCGCCCTACAAATCTTCCTCTTCG-3
(HindIII and NotI site underlined) in a Thermocycler (Bio-Rad)
under conditions at one cycle of 95uC for 2 min, 30 cycles of 95uC
for 1 min, 50uC for 1 min., and 72uC for 1.30 min, and finally one
cycle of 72uC for 10 min. Amplified PCR product was
electrophoresed in agarose gel and eluted from the gel by Gen
Elute Columns (Qiagen). Eluted product was ligated in pTZ57R/
T (T/A) cloning vector (Fermentas) and transformed into
competent DH5a cells. The transformants were screened for the
presence of recombinant plasmids with the LdPDI gene-specific
PCR under similar conditions as previously mentioned. Isolated
positive clones were sequenced from Delhi University (New Delhi)
and submitted to the National Center for Biotechnology
Information http://www.ncbi.nlm.nih.gov/nuccore/EU723849
(accession no. EU723849). LdPDI was further subcloned at the
HindIII and NotI site in bacterial expression vector- pET28a
(Novagen) as well as mammalian expression vector pcDNA3 for
expression under the control of a strong cytomegalovirus (CMV)
promoter. The expression of recombinant LdPDI protein
(rLdPDI) was checked in bacterial cells by transforming the pET
- LdPDI construct in Escherichia coli Rosetta strain. The transformed
cells were inoculated into 5-ml test tube Luria- Bertani medium
(LB) and allowed to grow at 37uC in a shaker at 220 rpm. Cultures
in logarithmic phase (at OD600 of ,0.5–0.6) were induced for 3 h
with 1.0 mM isopropyl-b-D-thiogalactopyranoside (IPTG) at
37uC. After induction, 1 ml cells were lysed in 100 ml sample
buffer (50 m M Tris-HCl (pH 8), 10% glycerol, 10% SDS, and
0.05% bromophenol blue, with 100 mM DTT) and whole cell
lysates (WCL) was analyzed by 12% SDS-PAGE (32). Uninduced
control culture was analyzed in parallel.
For purification 200 mL of LB medium containing 34 mg/mL
of chloramphenicol and 35 mg/mL kanamycin were inoculated
with E.coli. rosetta strain transformed with pET - LdPDI, and
grown at 37uC to an O.D.600 of ,0.6. Recombinant protein
expression was induced by addition of 1 mM (IPTG,Sigma) and
the culture was incubated for an additional 4 to 5 h. The rLdPDI
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2+chelating resin
to bind the His6-tag fusion peptide derived from the pET28a
vector. The cell pellet was resuspended in 4 mL of lysis buffer
(50 mM Tris-HCL (pH 8.0), 300 mM NaCl, and 20 mM
imidazole,) containing 1:200 dilution of protease cocktail inhibitor
(Sigma) and 1% Triton X-100, incubated for 30 min on ice with
1 mg/mL lysozyme (Sigma), and the suspension was sonicated for
10620 sec (with 30 s intervals between each pulse) on ice. The
sonicated cells were centrifuged at 15,000 g for 30 min, and the
supernatant was incubated at 4uC for 1 h with the 2 mL of Ni–
NTA Superflow resin (Qiagen, Hilden, Germany) previously
equilibrated with lysis buffer. After washing with buffer (50 mM
Tris-HCL(pH 8.0), 300 mM NaCl and 1% Triton X-100),
containing different concentrations of imidazole i.e. 20,50 and
100 mM, the purified rLdPDI was eluted with elution buffer
(50 mM Tris-HCL, 100 mM NaCl, and 250 mM imidazole,
pH 7.5). The eluted fractions were analyzed by 12% SDS–PAGE
and the gels were stained with Coomassie brilliant blue R-250
(Sigma–Aldrich, St. Louis, USA). The protein content of the
fractions was estimated by the Bradford method using bovine
serum albumin (BSA) as standard. The presence of endotoxin was
tested by QCL-1000H Chromogenic LAL kit (Lonza).
Production of polyclonal antibodies against the
recombinant Protein and Western blot analysis
The purified rLdPDI protein was used for raising antibodies in
New Zealand white rabbit. Rabbit was first immunized using
50 mg of rLdPDI in Freund’s complete adjuvant. After 15 days, the
rabbit was given 3 booster doses of 25 mg rLdPDI each in
incomplete Freund’s adjuvant at 2-weeks interval and blood was
collected for serum 8 days after the last immunization. For
immunoblotting experiment, purified rLdPDI protein and SLD
were resolved on 12% SDS–PAGE and transferred on to
nitrocellulose membrane using a semi-dry blot apparatus (Amer-
sham) [40]. After overnight blocking in 5% BSA, the membrane
was incubated with antiserum to the rLdPDI protein at a dilution
of 1:5000 for 120 min at room temperature (RT). The membrane
was washed three times with PBS containing 0.5% Tween 20
(PBS-T) and then incubated with goat anti-rabbit IgG HRP
conjugate (Bangalore Genie) at a dilution of 1:10,000 for1 h at
room temperature. Blot was developed by using diaminobenzidi-
ne+imidazole +H2O2 (Sigma).
Expression of pcDNA-LdPDI in mammalian cell line
The expression of pcDNA-LdPDI was further checked in
mammalian cells by transfecting the pcDNA-LdPDI construct in
Human Embryonic Kidney-293 T (HEK- 293T) cell line cells.
This cell line was commercially obtained from American Type
Culture Collection (ATCC). For transfection and vaccination
studies, endotoxin- free plasmid DNA was isolated using an
Endofree plasmid purification Maxi kit as per the manufacturer’s
protocol (Qiagen). For confirmation of the proteins expressed by
the pcDNA-LdPDI construct, 2610
5 HEK - 293T cells were
grown in four-chamber slides and transfected with the blank
pcDNA3 plasmid and pcDNA-LdPDI construct, in serum-free
DMEM (Life Technologies) using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. Expression was
confirmed by RT-PCR and western blotting. The lysate of stably
transfected HEK- 293T cells was prepared and subjected to SDS-
PAGE. Thereafter, the protein bands were electrophoretically
transferred to nitrocellulose membrane. To detect the expressed
protein, a primary polyclonal antibody against rLdPDI was used at
1:5000 dilution followed by 1:10000 dilution of HRP-conjugated
goat anti-rabbit IgG secondary antibody (Bangalore Genei,
Bangalore, India).
Patients and isolation of peripheral blood mononuclear
cells (PBMCs)
The study groups for human samples were as follows:
[1] Seven treated cured patients (4 males and 3 females, age
ranging from 7–40 years) from hyper-endemic areas of Bihar. All
the patients had received complete course of amphotericin B and
had recovered from VL. Samples were collected from 2 months to
1 year after the completion of treatment. Diagnosis was established
in all cases by demonstration of parasites in splenic aspirates and
found negative at the time of study.
[2] Five endemic household contacts (2 males and 3 females, age
range-15 to 40 years) who neither showed clinical symptoms nor
received any treatment for Kala-azar.
[3] Five infected patients (3 males and 2 females, age range- 5 to
40 years) showing clinical symptoms of Kala-azar.
[4] Five normal healthy donors (3 males and 2 females, age
range 20–30 years) from non-endemic areas, without any history
of leishmaniasis, served as negative control.
Heparinized venous blood (10 ml each) was collected from all
the study subjects and peripheral blood mononuclear cells
(PBMCs) were isolated from blood by Ficoll Hypaque density
gradient centrifugation (Histopaque 1077, Sigma, USA) as
described by Garg et al. [37]. A final suspension of 1610
6 cells/
ml was made in complete RPMI medium (cRPMI) after
determining cell viability by trypan blue staining method. These
were used for various immunological assays.
Treatment of L. donovani infected hamsters and isolation
of mononuclear cells (lymph node cells)
Approximately 20 hamsters, infected with 10
7 amastigotes
intracardially, were assessed one month later for parasitic burden
by splenic biopsy through a small incision in the upper left quarter
of the abdomen and a small piece of splenic tissue was cut and dab
smears were made on slides. The incised portion was stitched with
nylon suturing thread. Following biopsy, an adequate amount of
antibiotic powder (Neosporin) was applied on the stitched portion
and finally sealed with tincture benzoin. In addition, neosporin
sulphate (100 mg/kg of body weight) was also given orally the day
before and the day after the biopsy for healing. The smears were
fixed in methanol and stained with Giemsa stain and the number
of amastigotes/1000 cell nuclei was counted. The animals
harbouring .25–30 amastigotes/100 macrophage cell nuclei
were then treated with antileishmanial drug-Miltefosine (Zentaris,
Germany) at 40 mg/kg bodyweight daily for 5 days. The animals
were reassessed for complete cure by splenic biopsy performed on
day 30 post-treatment.
Mononuclear cells were separated from lymph nodes of cured,
infected as well as normal hamsters following the protocol of Garg
et al, [37] and a suspension of 10
6 cells/ml was made in cRPMI.
These cells were employed for lymphoproliferative assay and for
the estimation of NO production.
Assessment of prophylactic efficacy of pcDNA-LdPDI in
hamsters to Leishmania challenge
Four experimental groups each having 12–15 hamsters were
taken for the study. The hamsters of Group 1 was immunized
intramuscularly (i.m.) with pcDNA-LdPDI (100 ug/100 ul PBS/
animal) whereas groups 2 to 4 served as controls. The animals of
group 2 were vaccinated with 100 mg of pcDNA3 (blank vector)/
100 ml of PBS and that of group 3 served as unvaccinated but
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pcDNA-LdPDI or Leishmania infection served as normal control.
On day 7 and 14, two booster doses of 100 mg pcDNA-LdPDI
were given i.m. to group 1.Twenty-one days after the first
vaccination, all the vaccinated and unvaccinated control groups
were challenged intracardially with 10
8 late log phase promasti-
gotes of L. donovani. The weight of body, spleen and liver (on
necropsy) of hamsters of all of the experimental groups were
assessed, on necropsy, at different time intervals, i.e., on days 0, 60,
90 and 120 p.c. The assessment of parasite burden was done in
spleen, liver and bone marrow of vaccinated hamsters at different
time intervals, i.e. on days 0, 45, 90, 120 post-challenge (p.c.).
Peritoneal exudates cells, inguinal lymph nodes and blood were
also collected at these time points to obtain cells and sera for
evaluation of cellular and antibody responses as per protocols
described above. The criterion for prophylactic efficacy was the
assessment of parasite load as the number of amastigotes/1000 cell
nuclei in each organ in comparison to the unvaccinated controls
and the percentage inhibition (PI) was assessed in comparison to
the unvaccinated control by following formula [41] PI=(No. of
parasite count from infected control –No. of parasite from
vaccinated group/No. of parasite count from infected con-
trol)6100. DTH was performed by injecting 50 mg/50 mlo f
SLD in PBS intradermally into one footpad and PBS alone into
the other one of each of the vaccinated and unvaccinated controls.
The response was evaluated 48 h later by measuring the difference
in footpad swelling between the two with and without SLD for
each animal [42].
Immunological assay
Assessment of Lymphocyte proliferative responses (LTT)
in cured/exposed patients and hamsters. Lymphocytes
suspension (1610
6 cells/ml) of cured/exposed patients and
normal, infected (30 days p.c.) and cured hamsters was cultured
in 96-well flat bottom tissue culture plates (Nunc, Denmark). This
assay was carried out as per protocol described by Garg et al. [37]
with some modifications, wherein XTT (Roche diagnostics) was
used instead of
3H thymidine. About 100 ml of predetermined
concentration of mitogens, PHA (10 mg/ml Sigma, USA) for
Patient’s PBMCs, Con A (10 mg/ml, Sigma), for hamster’s
lymphocytes, as well as rLdPDI and SLD (10 mg/ml each) were
added to the wells in triplicate. Wells without stimulants served as
blank controls. Cultures were incubated at 37uCi naC O 2
incubator with 5% CO2 for 3 days in the case of the mitogens, and
for 5 days in the case of the antigens. Eighteen hours prior to
termination of experiment, 50 ml of XTT was added to 100 mlo f
supernatants of each well and absorbance measured at 480 nm
with 650 nm as reference wavelength.
Estimation of NO activity in macrophages of hamsters
and cell lines. Isolated lymphocytes from all the three study
groups of hamsters viz. Normal, infected (30 p.c.) and cured, were
suspended in culture medium and plated at 10
5 cells/well and
stimulated for 3 days in case of mitogen (LPS) and 5 days in case of
antigens (rLdPDI, SLD) at 10 mg/ml. The presence of NO was
assessed using Greiss reagent(Sigma, U.S.A) in the culture
supernatants of naive hamster peritoneal macrophages [37] after
the exposure with supernatant of stimulated lymphocyte’s. The
supernatants (100 ml) collected from macrophage cultures 24 h
after incubation was mixed with an equal volume of Greiss reagent
(Sigma, USA) and left for 10 min at room temperature. The
absorbance of the reaction was measured at 540 nm in an ELISA
reader [43]. The nitrite concentration in the macrophages culture
supernatant samples was extrapolated from the standard curve
plotted with sodium nitrite.
Assessment of Cytokine levels- IFN-c/IL-12/IL-10 in
lymphocytes of cured/endemic patients. Culture of
PBMCs (1610
6 cells/ml) from human patients was set up in 96-
well culture plates and rLdPDI was added in triplicate wells at a
concentration of 10 mg/ml. The level of IFN-c, IL-12 and IL-10
was estimated by enzyme-linked immunosorbent assay (ELISA)
(OptEIA set, Pharmingen) after 5 days of incubation with antigen
using supernatants. The results were expressed as picograms (pg)
of cytokine/ml, based on the standard curves of the respective
cytokine provided in the kit. The lower detection limits for various
cytokines were as follows: 4.7 pg/ml for IFN-c, 7.8 pg/ml for IL-
12p40, 7.0 pg/ml for IL-10.
Quantification of mRNA cytokines and inducible NO
synthase (iNOS) in hamsters by Real time-PCR. qRT-PCR
was performed to assess the expression of mRNAs for various
cytokines and iNOS in splenic cells. Splenic tissues were taken
from each of the 3 to 4 randomly chosen animals. Total RNA was
isolated using Tri-reagent (Sigma-Aldrich) and quantified by using
Gene-quant (Bio-Rad). One microgram of total RNA was used for
the synthesis of cDNA using a first-strand cDNA synthesis kit
(Fermentas). For qRT-PCR, primers were designed using Beacon
Designer software (Bio-Rad) on the basis of cytokines and iNOS
mRNA sequences available on PubMed [36] (Table 1). qRT-PCR
was conducted as per the protocol described earlier [44]. Briefly, it
was carried out with 12.5 ml of SYBR green PCR master mix (Bio-
Rad), 1 mg of cDNA, and primers at a final concentration of
300 nM in a final volume of 25 ml. PCR was conducted under the
following conditions: initial denaturation at 95uC for 2 min
followed by 40 cycles, each consisting of denaturation at 95uC
for 30 s, annealing at 55uC for 40 s, and extension at 72uC for
40 s per cycle using the iQ5 multicolor real-time PCR system (Bio-
Rad). cDNAs from infected hamsters were used as ‘‘comparator
samples’’ for quantification of those corresponding to test samples.
All quantifications were normalized to the housekeeping gene,
HPRT. A no-template control cDNA was included to eliminate
contaminations or nonspecific reactions. The cycle threshold (CT)
value was defined as the number of PCR cycles required for the
fluorescence signal to exceed the detection threshold value
(background noise). Differences in gene expression were
calculated by the comparative CT method [44]. This method
compares test samples to a comparator sample and uses results
obtained with a uniformly expressed control gene (HPRT) to
correct for differences in the amounts of RNA present in the two
samples being compared to generate a DCT value. Results are
expressed as the degrees of difference between DCT values of test
and comparator samples.
Measurement of antibody response in hamsters and
Cured patients. The level of IgG antibody and its isotypes in
sera samples of hamsters of different experimental groups as well
as in cured patient serum was measured as per protocol by Samant
et al. [44]. Briefly, 96-well ELISA plates (Nunc) were coated with
rLdPDI/SLD (0.2 mg/100 ml/well) overnight at 4uC and blocked
with 1.5% BSA at room temperature for 1 h. Sera was used at a
dilution of 1/100 for IgG, IgG1, and IgG2 and kept for 2 h at
room temperature. Biotin-conjugated mouse anti-Armenian and
Syrian hamster IgG, IgG1 and biotinylated anti-Syrian hamster
IgG2 (BD Pharmingen) for hamster and mouse anti human IgG,
IgG1 and IgG2 in case of human were added for 1 h at room
temperature at 1/1000 dilutions and were further incubated with
streptavidin-conjugated peroxidase at 1/1000 (BD Pharmingen)
for 1 h. Finally, the substrate O-phenylenediamine
dihydrochloride (Sigma-Aldrich) was added and the plate was
read at 492 nm.
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of hamsters belonging to group 4 was checked until day 180 p.c. in
comparison to the normal hamsters. Animals in all of the groups
were given proper care and were observed for their physical
conditions until their survival period. Survivals of individual
hamsters were recorded and mean survival period was calculated.
Results were expressed as mean6S.D. In each experiment 6–8
animals were used in each group. Two sets of experiments were
performed and the results were analyzed by one-way ANOVA test
followed by Dunnet’s or Tukey’s post which ever appropriate at
each case using Prism Graphpad software program. The upper
level of significance was chosen as p,0.001 (highly significant).
Ethics Statement. The study and the protocol was approved
by the Ethics committee of the Kala-azar Medical Research
Centre, Muzaffarpur (Protocol # EC-KAMRC/Vaccine/VL/
2007-01) and CDRI and all patients provided a written consent
before enrolment to this study. Experiments on the animals
(hamsters) were performed following the approval of the protocol
and the guidelines of Institutional Animal Ethics Committee
(IAEC) of the CDRI. The approval reference number is 150/09/
Para/IAEC dated 23.10.2009.
Results
LdPDI was cloned, sequenced, expressed in E. coli Rosetta
strain and HEK cell line
The LdPDI gene of L. donovani was successfully amplified, cloned
in T/A vector (Fig. 1A) and sequenced, which was 99%
homologous with L.infantum PDI (Table 2). It was further cloned
in bacterial expression vector pET28a (Fig. 1B), purified and
eluted at 250 mM imidazole concentration. The size of the eluted
rLdPDIs was ,58 kDa (Fig. 1C). Western Blot analysis of L.
donovani promastigotes lysates was performed with the polyclonal
anti- rLdPDI antibody which detected one dominant protein band
of ,55 kDa (Fig. 1D). Because the expression of recombinant
proteins by mammalian cells transfected with bacterial plasmid
DNA is a critical condition for the stimulation of the immune
system, the expression of the rLdPDI protein was initially assessed
in HEK-293T cells transfected with the pcDNA-LdPDI construct.
Transfected cells were cultured for 2–3 days and washed, and
expression of the recombinant proteins was assessed by SDS-
PAGE and Western blot analyses. Cells transfected with pcDNA-
LdPDI, expressed high levels of the recombinant protein as
detected by Western blotting (Fig. 1E) and was further confirmed
by RT-PCR (Fig. 1F)
rLdPDI induced strong lymphoproliferative and NO
responses in normal/infected/cured hamsters
The cellular responses of lymph node cells of cured hamsters
were assessed by XTT against the Con A (mitogen) and SLD as
well as rLdPDI antigens. The responses were compared with that
of normal as well as L. donovani infected groups that served as
controls. The normal control as well as cured Leishmania infected
group had shown significantly higher proliferative responses
against Con A as compared to L. donovani-infected group. The
results of the proliferative response of lymphocytes against rLdPDI
showed significantly higher stimulation in cured/infected hamsters
(mean OD 2.43760.11 and 1.98360.29) than SLD (mean OD
1.2760.28 and 0.96860.14). The difference was statistically
significant (p,0.001) (Fig. 2 A).
NO-mediated macrophage effector mechanism is known to be
critical in the control of parasite replication in the animal model
hence its production in peritoneal macrophages of cured hamsters,
was studied after 24 h of incubation in the presence of rLdPDI and
SLD. For comparison, NO production in mitogen (LPS)
stimulated and unstimulated cells served as positive and negative
controls respectively. NO production was recorded to be
significantly higher against rLdPDI (p,0.001) (Fig. 2 B).
rLdPDI stimulates PBMCs from Leishmania infected/
cured/endemic to proliferate and to express a
predominant Thl Cytokine Profile
We further analyzed PBMCs of cured patients, endemic and
non-endemic controls and L. donovani-infected donors for cellular
and cytokine responses. The cytokine responses in individual
donors in each study group were found to elicit different responses.
Proliferation and cytokine responses of PBMCs from patients with
active VL/cured/endemic were compared using rLdPDI and
SLD. Endemic control and cured patients exhibited relatively
higher mean OD values against PHA, i.e. 2.5560.027 and
2.7460.042 respectively. PBMCs from all the cured and active VL
patients proliferated in response to rLdPDI with mean OD values
of 2.3360.037 and 1.5260.052 higher values than SLD (mean
OD values of 1.1860.081 and 0.46760.189) respectively
(p,0.001) (Fig. 3 A). The results demonstrate that rLdPDI is a
potent T cell antigen recognized by a majority of active VL/
cured/endemic individuals in different stages or manifestations of
infection.
To assess the Th1/Th2 stimulatory potential of the rLdPDI, we
further estimated the cytokine levels viz. IFN-c, IL-12 and IL-10 in
PBMCs from cured/infected patients as well as in endemic and
non endemic contacts against rLdPDI. The levels of IFN-c and IL-
12 were observed to be higher in the supernatants of cured
patients with a range of 623–1470 pg/ml and 773–2145 pg/ml
respectively as compared to endemic contacts (344–1427 pg/ml
and 332–1553 pg/ml respectively). On the contrary, very low
levels of IL-10 cytokines against rLdPDI were detected in
supernatants of cured (17.15–40.12 pg/ml) patients followed by
endemic contacts (ranging from 15.10–35.48 pg/ml). PBMCs of
cured/endemic contacts generated a mixed Th1/Th2 cytokine
Table 1. Sequences of forward and reverse primers of
hamster cytokines used for quantitative real time -PCR.
S.N. Primer Primer Sequence
1 HPRT Forward 59 GATAGATCCACTCCCATAACTG 39
Reverse 59 TACCTTCAACAATCAAGACATTC 39
2T N F - a Forward 59 TTCTCCTTCCTGCTTGTG 39
Reverse 59 CTGAGTGTGAGTGTCTGG 39
3 IFN-c Forward 59 GCTTAGATGTCGTGAATGG 39
Reverse 59 GCTGCTGTTGAAGAAGTTAG 39
4 IL-12 Forward 59 TATGTTGTAGAGGTGGACTG 39
Reverse 59 TTGTGGCAGGTGTATTGG 39
5T G F - b Forward 59 ACGGAGAAGAACTGCTGTG 39
Reverse 59 GGTTGTGTTGGTTGTAGAGG 39
6 IL-4 Forward 59 GCCATCCTGCTCTGCCTTC 39
Reverse 59 TCCGTGGAGTTCTTCCTTGC 39
7 IL-10 Forward 59 TGCCAAACCTTATCAGAAATG39
Reverse 59 AGTTATCCTTCACCTGTTCC 39
8 iNOS Forward 59 CGACGGCACCATCAGAGG 39
Reverse 59AGGATCAGAGGCAGCACATC 39
doi:10.1371/journal.pone.0035670.t001
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of IFN-c and IL-12p40 were noticed in response to SLD in cured/
endemic contacts (Fig. 3 B–D). We were not able to detect these
cytokines against rLdPDI in infected and non endemic individuals
(data not shown).
Serum of cured VL patients exhibited high level of IgG2
against rLdPDI
The estimation of the level of antibody- IgG and its isotypes in
the serum of cured patients revealed a higher IgG2 response (mean
OD, 2.19260.135 and 0.39260.12) than non endemic patient-
s(mean OD, 0.08760.025) (Fig. 4). The difference was statistically
significant (p,0.001). However, the IgG1 response was not
significantly different between the cured and the non endemic
individuals (mean OD, 0.3360.002 versus 0.2960.015; p.0.5).
The IgG2 level in cured patients serum was found to be .10 fold
higher than non endemic individuals.
Vaccination with pcDNA-LdPDI generates optimum
protection in hamsters against L. donovani-challenges
Encouraged with the ability of rLdPDI to generate a Th1 type
profile, we further evaluated the prophylactic efficacy of pcDNA-
LdPDI construct in hamsters against L. donovani challenges. The
pcDNA-LdPDI vaccinated hamsters were found to be optimally
protected (,90%) from the L. donovani challenge. No protective
effect was seen when hamsters were immunized with the control
vector.
The vaccinated animals gained weight with time similarly as in
normal animals whereas there was significant weight loss
(p,0.001) in the animals of the infected and vector control
groups (Fig. 5A). There was an absence of hepatosplenomegaly in
the vaccinated group that is normally associated with the challenge
infection (Fig. 5 B&C). An increase from ,10
2 to ,10
4 parasites
in all of the groups, except in the pcDNA-LdPDI -vaccinated
group, was seen in Giemsa-stained splenic smears from days 45 to
Figure 1. Molecular characterization of Leishmania donovani Protein disulfide isomerise (LdPDI). (A) Clone confirmation of LdPDI in TA and
pET28a vector. M: 1 kb molecular mass marker; Lane 1: undigested plasmid, Lane 2: Hind III and NotI – digested TA- LdPDI. (B) Clone confirmation in
pET28a. M: 1 kb molecular mass marker; Lane 1: Hind III and NotI – digested pET- LdPDI, Lane 2: Undigested pET- LdPDI. (C) Purification and elution of
rLdPDI at 250 mM of imidazole concentration. M- Molecular wt. Markers, Lane 1&2: wash fraction, Lane 3 & 4: eluted protein. (D) Western blot with
whole cell lysate and SLD of L. donovani, M- Molecular wt. markers Lane 1: purified protein, Lane 2&3 WCL and SLD respectively of L. donovani. (E)
Western blot of transfected and control HEK cells, M- Molecular wt. Markers Lane 1: pcDNA control, Lane 2: transfected with pcDNA-LdPDI. (F)
Confirmation of expression in HEK cell line by RT-PCR. M- 1 kb molecular mass marker Lane 1: pcDNA control, Lane 2: pcDNA-LdPDI transfected.
doi:10.1371/journal.pone.0035670.g001
Table 2. Homology of LdPDI of L. donovani with other
Leishmania species.
Species Homology (%)
Leishmania infantum 99
Leishmania major 94
Leishmania braziliensis 84
doi:10.1371/journal.pone.0035670.t002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35670Figure 2. Cellular responses of rLdPDI of L. donovani in hamsters. (A) LTT response of mononuclear cells (lymph nodes) from normal, L.
donovani infected (30 day p.c.) and treated hamsters in response to Con A, SLD and rLdPDI at 10 mg/ml each. Proliferation was represented as mean
OD of stimulated culture - mean OD of unstimulated control. Each bar represents the pooled data (mean 6 S.D. value) of 6 hamsters and the data
represent the means of triplicate wells 6 the S.D of each hamster. (B) Nitric oxide production (mM) by peritoneal macrophages of hamsters (n=5). The
peritoneal macrophages were primed with the supernatants of stimulated lymphocytes (3 days with mitogen and 5 days with antigens) of normal,
infected and cured hamsters in response to rLdPDI, SLD and LPS respectively at10 mg/ml each. The estimation of NO production was done using
Greiss reagent in supernatants collected from macrophage cultures 24 h after incubation and the absorbance of the reaction product was measured
at 540 nm. Significance values indicate the stimulation of lymphocytes difference between the infected and cured in response to rLdPDI and
compared with SLD (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g002
Figure 3. Cellular responses of rLdPDI of L. donovani in human PBMCs. LTT response of PBMCs in non endemic normal/healthy individuals,
endemic contacts, leishmania infected patients and cured individuals. Each bar represent the mean OD 6 SD value of stimulated PBMCs of each
group (A); Th1 and Th2 cytokine production (B–D) in PBMCs from individuals of cured VL patients (7) and endemic controls (5) in response to rLdPDI
and SLD antigens, each data point represents one individual. Values are given as concentration in pg/ml. The statistical significances are given
between infected vs cured and infected vs endemic individuals. (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g003
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decreased from 2610
2 on day 45 to a very low level (p,0.001) by
day 120 p.c. Similarly, in liver and bone marrow, parasite loads
decreased sharply after day 45 p.c. and parasites were almost
absent by day 180 p.c. in the same vaccinated group. Cultivation
of the spleen, liver, and lymph node tissues from the vaccinated
hamsters in vitro yielded no promastigotes after prolonged
incubation for 3 wk.
The pcDNA-LdPDI -vaccinated hamsters survived the chal-
lenges of L.donovani and remained healthy more than 8 months. In
contrast, hamsters vaccinated with the pcDNA3 vector and
infected control survived for only 2–3 months.
pcDNA-LdPDI vaccination stimulates DTH, mitogenic and
Leishmania-specific cellular responses
DTH, an index of cell mediated immunity in vivo, and an
antigen specific in vitro T cell proliferation assay revealed the status
of cellular responses generated in vaccinated animals. We were
therefore interested to see the DTH and proliferative responses
elicited by vaccinated and challenged animals.
pcDNA-LdPDI -vaccinated hamsters displayed significant DTH
responses, which increased progressively and was higher than
those of the control groups (p,0.05) at all time points for the
duration of the experiments for up to 120 days (Fig. 6 A). In vitro
stimulation of the lymphocytes with Con A showed comparable
proliferative responses at high levels in all of the groups when
assayed before challenges. Cells from pcDNA-LdPDI -vaccinated
hamsters produced a significantly higher response (p,0.001),
which reached almost to the maximum on day 90 (Fig 6 B&C) as
compared to infected and vector control against SLD.
NO is the critical killing effector molecule against leishmaniasis
produced by IFN-c stimulated and inducible NO synthase induced
classical macrophages. Lymphocyte-mediated activation of mac-
rophages to produce NO for leishmanicidal activities was found to
differ between control and experimental groups of hamsters.
Supernatants from stimulated lymphocytes of hamsters immunized
with the pcDNA-LdPDI, when incubated with naive macrophages
produced significant (p,0.001) amounts of nitrite (18 mM) which
was ,2 fold more than that of unimmunized infected and vector
controls and ,4-fold more than the normal control group on day
90 p.c.Fig. 6 D&E).
pcDNA-LdPDI vaccination generates Th1-type cytokine
profile as determined by quantitative real-time PCR
It is well established that the cytokine milieu at the initiation of
infection is critical in determining disease outcome [45,46]. So to
understand the interplay between the disease healing inflamma-
tory cytokines, IFN-c and IL-12 as well as disease associated
cytokines, IL-10 and IL-4, we sought to investigate the expression
of these cytokines and the level of iNOS transcript, which play
major role in leishmaniasis control, in infected control as well as
vaccinated groups by qRT-PCR.
The expression of iNOS transcripts was observed to be
significantly elevated (p,0.001) in pcDNA-LdPDI vaccinated
hamsters on day 45 by .2 fold and found to be increased by
,4 fold at D 90 p.c. (Fig. 7 A). Its level was much lower in vector
and infected control groups. Similar was the case with IL-12 which
was least expressed in the infected group on day 90 p.c, but was
significantly expressed by ,5 fold (p,0.001) in vaccinated
hamsters on days 90 p.c. (Fig. 7 B). The expression of IFN-c,
although variable at different time points, was suppressed in the
infected group on day 90.p.c, but was significantly higher in the
vaccinated group on this time point (p,0.001) (Fig. 7 C). The
expression of TNF-a was also significantly higher by ,6 fold
(p,0.05) in the vaccinated group in comparison to L. donovani-
infected group (Fig. 7 D). TGF-b mRNA expression was clearly
up-regulated in the vector and infected groups. In contrast,
mRNA expression for this cytokine was drastically suppressed in
vaccinated group (Fig. 7 E). The level of IL-4, an established Th2
cytokine, was found to be suppressed in the vaccinated hamsters
group and the level of Th1 suppressive cytokine IL-10 was noticed
significantly higher in the vector and infected control groups as
compared to the vaccinated group (Fig. 7 F&G).
pcDNA-LdPDI vaccination alters Leishmania-specific IgG
and its isotypes
The serum levels of leishmanial antigen-specific IgG and its
isotypes (IgG1 and IgG2) from all of the groups were assessed by
ELISA. The anti-Leishmania IgG and IgG1 were elevated
progressively with time to a high level in all the experimental
groups, except the pcDNA-LdPDI vaccinated, in which case they
remained essentially the background levels of the infected and
vector immunized groups. In contrast, pcDNA-LdPDI vaccinated
animals were the only group that showed a significant elevation by
2- to 3 fold over the others (p,0.001) in the level of IgG2 (Fig. 8).
As a measure of CMI, the elevation of IgG2 was consistent with
the development of effective immune responses. These results are
in synchrony with the high level of IFN-c, as well as IL-12 cytokine
responses and suggest that the CD4+ T-cell response elicited by
the pcDNA-LdPDI vaccine is preferentially of the Th1 phenotype.
Discussion
In Leishmania species, Protein disulfide isomerase (PDI) - a
redox chaperone, is reported to be involved in its virulence and
survival. Several studies have described the virulence factors as
potentially immunogenic in humans as well as in rodents (mice)
and dogs [47,48,49].
PDI has been identified as a Th1 stimulatory protein from a
sub-fraction of soluble Leishmania antigen through proteomics,
belonging to the molecular weight range of 89.9 to 97.1 kDa [50].
Meek et al. [51] have detected IgG specific to four LaPDIs
(especially to the 52-kDa PDI). Further, Ben Achour et al. 2002
Figure 4. Antibody levels (OD value) in cured patients and non
endemic individuals (6 each) against rLdPDI. Each bar represents
the pooled data (mean6SD value) of three replicates. Significance
values indicate the difference between the immunized group and
normal group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g004
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and that there is a correlation between B cell activation/Ab
production and lesion progression in Leishmania-infected patients
and experimental animals [52,53]. Padilla et al. [54] reported a
unique PDI of ,15 kDa, which was found to be essential for
survival of L. donovani. In the present study, we have cloned LdPDI
which exhibited very close homology with L. infantum PDI to the
tune of 99%. Immunoblot study of L. donovani promastigotes lysate
with the polyclonal anti-rLdPDI antibody has revealed one
dominant protein of ,55 kDa. This protein was identified earlier
at high molecular weight range in proteomic studies which is in
contrast to its observed molecular mass. This could be attributed
to the post-translational modifications which are widely prevalent
in Leishmania [30,55].
Further, to evolve its function, LdPDI was expressed in the E.
coli Rosetta strain with pET28a vector and in HEK mammalian
cells (at the RNA and protein levels using the pcDNA3 vector).
The successful delivery and the expression of the cloned LdPDI in
the HEK cell line further authenticate its evaluation as a DNA
vaccine candidate.
The protein was further characterized for its immunogenicity in
vitro. We have reported earlier that a T cell response develops
when cells from the cured patients from Leishmania endemic
regions are stimulated with SLD and its fractions and subfractions
[37,56]. rLdPDI, being one of the Th1 stimulatory protein
identified from the subfraction of SLD in the range of 89.9 to
97.1 kDa, when was subjected to re-evaluation for its stimulatory
potential in Leishmania infected and cured hamsters, induced better
Figure 5. Body weight (A), spleen weight (B) and liver weight (C) in gm of normal, infected control, vector (pcDNA) control as well as
pcDNA-LdPDI vaccinated hamsters. Parasite burden (number of amastigotes per 1000 cell nuclei) in the spleen (D), liver (E), and bone marrow (F)
of infected control, vector (pcDNA) control as well as pcDNA-LdPDI vaccinated hamsters on days 0, 45, 90, 120, and 180 p.c.. Significance values
indicate the difference between the vaccinated groups and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g005
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nicity was further validated successfully in endemic non-immune
donors (household contacts without any clinical symptoms) and in
immune patients of VL that were cured either with amphotericin
B or miltefosine.
Due to the existence of dichotomy in the human system, there
has been reservation in accepting human Th1 and Th2 to the
rodent Th1 and Th2 subsets. Moreover, in murine VL, while the
self-limiting infection pattern does not simulate the human profile,
the systemic infection of the hamster with L. donovani is very similar
to human Kala- azar, as it results in a relentlessly increasing
visceral parasite burden, progressive cachexia, hepatosplenomeg-
aly, pancytopenia, hypergammaglobulinemia, and, ultimately,
death [36]. Hence, analysis of cellular immune response of the
rLdPDI was carried out using hamsters’ lymphocytes/macro-
phages in order to correlate the observations made with the
human lymphocytes. We have previously shown that the cellular
responses to the fractions and subfractions of L. donovani
promastigotes were similar in endemic controls/cured patients of
VL, as well as in hamsters, indicating that the results so obtained
with the hamster could be translated into humans [37,56].
In the absence of cytokine reagents against hamsters, in this
study we have observed the effect of rLdPDI on lymphocyte
proliferation and NO production by peritoneal macrophages of
hamster. It is well documented that in case of leishmanial
infections, macrophages become activated by IFN-c released from
Figure 6. Cellular response against SLD in normal, infected control, vector (pcDNA) control as well as pcDNA-LdPDI vaccinated
hamsters at different time intervals post challenge. (A), DTH response (mm). (B–C), LTT response (mean OD value) to SLD and Con A on days
45 (B–C) and 90 post challenge. (D–E), NO production (mM) to LPS and SLD in the naive macrophages coincubated with supernatants of lymphocytes
isolated from pcDNA-LdPDI -vaccinated hamsters in comparison to the unimmunized infected controls, vector-immunized controls, and uninfected
normal hamsters on day 45 and day 90 post challenge. Significance values indicate the difference between the vaccinated groups and infected group
(*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g006
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35670Figure 7. Splenic iNOS and Th1/Th2 cytokine mRNA expression profile analysis of normal and vaccinated hamsters on days 45 and
90 p.c. by quantitative real-time –PCR. Significance values indicate the difference between the vaccinated group and infected group (*, p,0.05;
**, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g007
Figure 8. Anti- leishmania-specific IgG and its isotypes IgG1 and IgG2 in pcDNA-LdPDI -vaccinated hamsters in comparison to the
unimmunized infected hamsters on days 45 and 90 p. c.. Significance values indicate the difference between the vaccinated group and
infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0035670.g008
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parasites through the production of several mediators, principal
among which is NO [57,58]. rLdPDI gave significantly higher
cellular responses viz. lymphoproliferative as well as NO release
against all the cured hamsters in comparison to normal and
infected ones.
Some of the recombinant antigens have previously been shown
to induce lymphocyte proliferation and IFN-c production in
subjects cured of visceral and in patients with cutaneous or
mucosal leishmaniasis [59,60]. Since recovery from Leishmania
infection, relies on the induction of the Th1 response [61,62] with
production of IFN-c and IL-12 and enhanced expression of NO
synthase [57,63], in this study also we have observed that in
response to rLdPDI, there was a release of very high amount of
IFN-c and IL-12p40, in endemic control and cured patients of VL
and suppression of IL-10 as well. However, the overall
proliferative/cytokine response of T-cells of endemic controls
was not as high as was observed in recovered ones. The
observation that rLdPDI stimulated T cells from cured/endemic
individuals to proliferate and produce IFN-c suggests that PBMCs’
response to rLdPDI may be associated with protective immunity.
We have also detected very high level of IgG2, a marker for Th1
response, in cured patients’ serum against rLdPDI, reflecting its
Th1 stimulatory potential.
Encouraged with these observations we further evaluated the
prophylactic potential of LdPDI as a plasmid DNA vaccine to L.
donovani challenges. It has been shown in a variety of experimental
models of infection that vaccination with plasmid DNA induces
protective immunity through both MHC class I- and class II-
restricted T cell responses [24]. On the other hand, vaccination
with conventional protein, in general, induces MHC class II- but
not class I-restricted responses. For those infections in which IFN-c
and/or CTL responses may be required, the ability of DNA
vaccination to elicit an MHC class I response may be
advantageous over conventional protein vaccination in providing
a more broad-based and potentially durable immune response. On
the basis of this view, the naive hamsters were vaccinated with
pcDNA-LdPDI and challenged with the virulent strain of L.
donovani. Interestingly, the immunized hamsters survived the lethal
challenge and remained healthy after the termination of the
experiment at day 180 p.c., whereas all non-immunized and blank
vector-immunized hamsters succumbed to the lethal L. donovani
challenge within 3–4 months p.c.
A major factor of the immune mechanism(s) is the development
of strong cell-mediated immunological (CMI) responses like T-cell
responses, NO production and DTH responses which are
responsible for protection and are also supposed to contribute to
healing in VL [29,64,65,66]. In the present study, all the pcDNA-
LdPDI - vaccinated hamsters challenged with L. donovani have
shown a specific active T-cell response because they displayed
significant lympho-proliferative responses after challenge as
compared to non-immunized infected and healthy control
hamsters where it was severely impeded. Further, the supernatant
of SLD-stimulated lymphocytes from pcDNA-LdPDI -vaccinated
hamsters produce a remarkable level of NO in the macrophages of
naive hamsters which also support the view regarding the up-
regulation of iNOS by Th1 cell-associated cytokines and confirms
that the NO-mediated macrophage effector mechanism is critical
in the control of parasite replication in the animal model [67].
Moreover, successful vaccination of humans and animals is often
related to antigen-induced DTH responses in vivo and T-cell
stimulation with antigen in vitro [36,68], suggesting a correlation
between cell mediated immune responses and immunity to
infection in this model. Here too, a low level of parasite-specific
DTH responses observed in infected and vector control animals
can be correlated with disease progression in hamsters which, on
the other hand, was strongly elevated in hamsters immunized with
pcDNA-LdPDI vaccine. Apart from diminished cellular responses,
active VL is also associated with the production of high levels of
the Leishmania specific antibody, which is observed before detection
of parasite-specific T cell response [69]. It has been well known
that as a measure of CMI, the elevation of IgG2, which was
significantly and consistently prominent in the vaccinated group of
this study, is consistent with the development of effective immune
responses [44] together with the progressive elevation of the anti-
Leishmania IgG and IgG1 in all the groups except the vaccinated
one, suggested that protection against leishmaniasis is induced by a
strong T cell response [70,71]. The presence of a comparable
existence of Th1 and Th2 clones producing both IFN-c and IL-4
obtained from patients cured of VL encouraged us to assess
whether the protective response which was utmost elicited by
pcDNA-LdPDI vaccination in hamsters can reflect this feature of
clinical findings [72,73,74]. Notably, we have observed that
vaccination with pcDNA-LdPDI resulted in significant elevation of
Th1 type of immune response. The transcript of IFN-c,a
signature cytokine of the Th1-type response having a dominant
effect on macrophage microbicidal responses and other effector
killing mechanisms, along with TNF-a, often reported to act in
concert to activate iNOS for the production of NO [75,76], were
found to be down-regulated [64] in infected hamsters, whereas
their expression was observed to be increased many fold in the
immunized hamsters. The key macrophage deactivating Th2
cytokines- IL-10 and IL-4 have a definitive association with an
acute phase of VL during which their level increase progressively
in tissues but were not detectable after successful cure [17,36].
Commensurate with these observations, an extreme down-
regulation of IL-10 and IL-4 mRNA levels was observed in
pcDNA-LdPDI -vaccinated hamsters as compared with infected
control hamsters [77]. Furthermore, the presence of IL-10 as well
as IFN-c was reported in patients with acute VL whereby only IL-
10 levels decreased remarkably with disease cure [78]. In addition,
there are reports that primary Th1 cell-mediated antileishmanial
events induced in IL-10-deficient mice require IFN-c that is
largely induced by IL-12 [29,79]. However, in the present study,
IL-12 was completely down-regulated in infected hamster,
whereas high level of IL-12 mRNA transcript was found in
vaccinated hamsters. TGF-b, a pleiotropic cytokine with diverse
functions, is known to be expressed at a moderate level even in
normal hamsters, [29,36,64] was observed to be markedly
upregulated in L. donovani infected hamsters but severely down
regulated in vaccinated animals. Furthermore, there was apparent
down-regulation of IL-4 expression in all of the immunized
hamsters throughout the experiment. Finally, unlike mice where
IL-4 and IL-12 direct IgG subclass switching of IgG1 and IgG2a,
respectively, such distinct IgG classes remains obscure in hamsters
[42,80]. It has been well established that IgG and IgG1 antibody
increase in titre with the L. donovani loads [29]. Therefore, the very
low level of these antibodies is thus consistent with the decreasing
parasite loads seen in the vaccinated group. The significant
increase in the IgG2 levels only in vaccinated animals is indicative
of enhanced CMI.
In summary, this study demonstrates for the first time the
immunogenicity of rLdPDI protein both in vitro as well as in vivo,
eliciting a dominant Thl-type cytokine profile. In addition, the
significant prophylactic efficacy of the pcDNA-LdPDI makes it a
strong and promising prophylactic vaccine candidate.
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